Barbara Pahud

Barbara Pahud

Auto-generated profile, based on publicly available information

Barbara Pahud

Children's Mercy Hospital

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Pediatrics
Verified
Journal Article
Closed access
PDF file
BRBrian Rha
Brian Rha
ACAaron T. Curns
Aaron T. Curns
JLJoana Y. Lively
Joana Y. Lively
ACAngela P. Campbell
Angela P. Campbell
JEJanet A. Englund
Janet A. Englund
SGSusan I. Gerber
Susan I. Gerber
BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of hospitalized acute respiratory illness (ARI) among young children. With RSV vaccines and immunoprophylaxis agents in clinical development, we sought to update estimates of US pediatric RSV hospitalization burden. METHODS: Children <5 years old hospitalized for ARI were enrolled through active, prospective, population-based surveillance from November 1, 2015, to June 30, 2016, at 7 US pediatric hospital sites. Clinical information was obtained from parent interviews and medical records. Midturbinate nasal and throat flocked swabs were collected and tested for RSV by using molecular diagnostic assays at each site. We conducted descriptive analyses and calculated population-based rates of RSV-associated hospitalizations. RESULTS: Among 2969 hospitalized children included in analyses, 1043 (35%) tested RSV-positive; 903 (87%) children who were RSV-positive were <2 years old, and 526 (50%) were <6 months old. RSV-associated hospitalization rates were 2.9 per 1000 children <5 years old and 14.7 per 1000 children <6 months old; the highest age-specific rate was observed in 1-month-old infants (25.1 per 1000). Most children who were infected with RSV (67%) had no underlying comorbid conditions and no history of preterm birth. CONCLUSIONS: During the 2015–2016 season, RSV infection was associated with one-third of ARI hospitalizations in our study population of young children. Hospitalization rates were highest in infants <6 months. Most children who were RSV-positive had no history of prematurity or underlying medical conditions, suggesting that all young children could benefit from targeted interventions against RSV.

1 February 2011 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
BPBarbara A. Pahud
Barbara A. Pahud
CGCarol A. Glaser
Carol A. Glaser
CDCornelia L. Dekker
Cornelia L. Dekker
AAAnn M. Arvin
Ann M. Arvin
DSD. Scott Schmid
D. Scott Schmid
Background. Since the introduction of live attenuated varicella zoster virus (VZV) vaccine in 1995 there has been a significant reduction in varicella incidence and its associated complications, but the impact on VZV-associated central nervous system (CNS) disease has not been assessed. Methods. In this descriptive study we evaluated patients referred to the California Encephalitis Project from 1998 to 2009 with VZV PCR-positive cerebrospinal fluid (CSF). Epidemiological, clinical, and laboratory data were collected using a standardized case form. Specimens were genotyped using multi-single nucleotide polymorphism (SNP) analysis. Results. Twenty-six specimens were genotyped from patients 12–85 years of age (median, 46 years). Clinical presentations included meningitis (50%), encephalitis (42%), and acute disseminated encephalomyelitis (ADEM) (8%). Only 11 patients (42%) had a concomitant herpes zoster rash. Genotype analysis identified 20 European Group (Clade1, Clade 3) strains; 4 Asian (Clade 2) strains, and 2 Mosaic Group (Clade 4, Clade VI) strains. One specimen was recognized as vaccine strain by identifying vaccine-associated SNPs. Conclusions. VZV continues to be associated with CNS disease, with meningitis being the most frequent clinical presentation. CNS VZV disease often presented without accompanying zoster rash. Sequencing data revealed multiple genotypes, including 1 vaccine strain detected in the CSF of a young patient with meningitis.

1 December 2016 in Vaccine
Verified
Journal Article
Closed access
CBCaterina Bonetto
Caterina Bonetto
FTFrancesco Trotta
Francesco Trotta
PFPatrizia Felicetti
Patrizia Felicetti
GAGraciela S. Alarcón
Graciela S. Alarcón
CSCarmela Santuccio
Carmela Santuccio
JBJan Bonhoeffer
Jan Bonhoeffer

1 March 2018 in Medicine
Verified
Journal Article
Open access
JWJoseph Wheat
Joseph Wheat
TMThein Myint
Thein Myint
YGYing Guo
Ying Guo
PKPhebe Kemmer
Phebe Kemmer
CHChadi Hage
Chadi Hage
AAAlbert Anderson
Albert Anderson
Central nervous system (CNS) involvement occurs in 5 to 10% of individuals with disseminated histoplasmosis. Most experience has been derived from small single center case series, or case report literature reviews. Therefore, a larger study of central nervous system (CNS) histoplasmosis is needed in order to guide the approach to diagnosis, and treatment. A convenience sample of 77 patients with histoplasmosis infection of the CNS was evaluated. Data was collected that focused on recognition of infection, diagnostic techniques, and outcomes of treatment. Twenty nine percent of patients were not immunosuppressed. Histoplasma antigen, or anti-Histoplasma antibodies were detected in the cerebrospinal fluid (CSF) in 75% of patients. One year survival was 75% among patients treated initially with amphotericin B, and was highest with liposomal, or deoxycholate formulations. Mortality was higher in immunocompromised patients, and patients 54 years of age, or older. Six percent of patients relapsed, all of whom had the acquired immunodeficiency syndrome (AIDS), and were poorly adherent with treatment. While CNS histoplasmosis occurred most often in immunocompromised individuals, a significant proportion of patients were previously, healthy. The diagnosis can be established by antigen, and antibody testing of the CSF, and serum, and antigen testing of the urine in most patients. Treatment with liposomal amphotericin B (AMB-L) for at least 1 month; followed by itraconazole for at least 1 year, results in survival among the majority of individuals. Patients should be followed for relapse for at least 1 year, after stopping therapy.

1 January 2013 in Vaccine
Verified
Journal Article
Closed access
FPFrancesca Poli
Francesca Poli
SOSebastiaan Overeem
Sebastiaan Overeem
GLGert Jan Lammers
Gert Jan Lammers
Giuseppe PlazziGiuseppe Plazzi
Giuseppe Plazzi
MLMichel Lecendreux
Michel Lecendreux
JBJan Bonhoeffer
Jan Bonhoeffer

1 December 2013 in Vaccine
Verified
Journal Article
Closed access
NHNeal A. Halsey
Neal A. Halsey
MGMari Griffioen
Mari Griffioen
SDStephen C. Dreskin
Stephen C. Dreskin
CDCornelia L. Dekker
Cornelia L. Dekker
RWRobert Wood
Robert Wood
JKJohn M. Kelso
John M. Kelso